Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide

Completed · Phase 2

Conditions studied: Multiple Myeloma

In brief

The purpose of this research is to study how helpful the combination of thalidomide and Pamidronate is in controlling multiple myeloma and to study any side effects that may be experienced.

Key facts

Study ID

NCT00083408

Run by

University of Arkansas

People needed

20

Starts

1998-03-01

Expected to finish

2005-05-01

Last updated by the study team

2010-07-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have a diagnosis of Multiple myeloma with poor hematopoietic reserve (platelet count <100,000 OR inability to collect adequate PBSC to support autologous transplant (4X106 CD34+cells/kg OR WBC <2,000)
• Patients must not be eligible for UARK 98-035
• Patients must be at least 6 weeks beyond previous chemotherapy
• All patients must be informed of the investigational nature of this study and must sign a written informed consent in accordance with UAMS Human Research Advisory Committee and federal guidelines

You may not qualify if…

• Prior bisphosphonate therapy within 30 days prior to study entry
• Serum creatinine > 5 mg/dl, ascites, or serum direct bilirubin > 2.5 mg/dl
• Prior plicamycin or calcitonin within 2 weeks of study entry
• Severe cardiac disease, unstable thyroid disease, or epilepsy

Where it is running

• University of Arkansas for Medical Sciences/MIRT — Little Rock, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.